PepGen Inc.
Close on Oct 19, 2026
- Market cap
- $186.85M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | During market hours | – | $-0.26 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | During market hours | – | $-0.27 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-0.52 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-0.70 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | $-0.92 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 24, 2025 | Before market open | – | $-0.68 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-0.66 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.87 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | During market hours | – | – | – |
Press releases
Announcements PepGen filed with the SEC
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PGN-EDODM1 – Myotonic Dystrophy Type 1 (DM1)
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Forward-Looking Statements This presentation contains forward-looking
Regulation FD disclosure · EX-99.1 to Form 8-K
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
March 2026 FREEDOM2-DM1 5 mg/kg MAD Cohort Data Update
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PGN-EDODM1 – Myotonic Dystrophy Type 1 (DM1)
Regulation FD disclosure · EX-99.1 to Form 8-K
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
PepGen Announces Regulatory Updates on FREEDOM2
Results of operations · Other events · EX-99.2 to Form 8-K
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
Other events · EX-99.1 to Form 8-K
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PGN-EDODM1 – Myotonic Dystrophy Type 1 (DM1)
Regulation FD disclosure · EX-99.1 to Form 8-K
PepGen Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
PepGen Announces Pricing of $100 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,”
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PepGen to Focus on Development of Promising DM1 Program Following
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the underlying cause of serious genetic neuromuscular and neurological diseases
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
Other events · EX-99.1 to Form 8-K
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
February 24, 2025 FREEDOM-DM1 5 and 10 mg/kg Clinical Data Update
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
PepGen Announces CONNECT Program Updates
Other events · EX-99.1 to Form 8-K
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51
Other events · EX-99.1 to Form 8-K
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PepGen Announces Presentations at the 29 th Annual Congress of the
Other events · EX-99.1 to Form 8-K
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
Other events · EX-99.1 to Form 8-K
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PepGen Announces Positive Data from Low-Dose Cohort of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,”
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PepGen Announces Executive Team Promotions
Other events · EX-99.1 to Form 8-K
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K